The practice of the clinical guidelines for the diagnosis and treatment of chronic heart failure applying in the city hospitals of Saint Petersburg
DOI:
https://doi.org/10.21638/spbu11.2023.102Abstract
Chronic heart failure is one of the main causes of mortality in Russia. Improving the medical care system for patients with chronic heart failure is currently associated with the introduction of guidelines, the application of which has become mandatory in Russia since of 2022. Aim to study whether the prescriptions set out in the discharge records of the St Petersburg city hospitals correspond to the provisions of the current guidelines on the chronic heart failure diagnosis and treatment. The material for the study was the discharge records of 101 patients with chronic heart failure who were treated in the city hospitals of St Petersburg in 2022. Echocardiography was performed in all patients, while brain natriuretic peptides were not measured in either case. Drugs from various groups of the renin-angiotensin-aldosterone system
blockers were recommended in 86.1 % of patients. Patients with reduced left ventricular ejection fraction most often received a Sacubitril/Valsartan (56.9 %). Beta-blockers in 84.2 %, and mineralocorticoid receptor antagonists were — in 94.1 % of cases. Therapy with the use of these three groups of drugs was received by 67.3 % of patients. Inhibitors of sodium-glucose co-transporter type 2 were recommended in 7.9 %, in 2 cases in addition to triple therapy. Loop diuretics were recommended in 88.1 % of cases. Therapy of patients with chronic heart failure who were treated in 2022 is more in line with the provisions of the current guidelines than in previous years, however, a number of problems remain unresolved.
Keywords:
chronic heart failure, clinical guidelines, pharmacoepidemiology, medical prescriptions, dose
Downloads
Download data is not yet available.
References
Литература
Хроническая сердечная недостаточность. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25, № 11. C. 311–374. https://doi.org/10.15829/1560-4071-2020-4083
Виноградова Н. Г., Поляков Д. С., Фомин И. В. Анализ смертности у пациентов с ХСН после декомпенсации при длительном наблюдении в условиях специализированной медицинской помощи и в реальной клинической практике // Кардиология. 2020. T. 60, № 4. C. 91–100. https://doi.org/10.18087/cardio.2020.4.n1014
Groenewegen A., Rutten F. H., Mosterd A., Hoes A. W. Epidemiology of heart failure // European Journal of Heart Failure. 2020. Vol. 22, no. 8. P. 1342–1356. https://doi.org/10.1002/ejhf.1858
Поляков Д. С., Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Артемьева Е. Г., Бадин Ю. В., Бакулина Е. В., Виноградова Н. Г., Галявич А. С., Ионова Т. С., Камалов Г. М., Кечеджиева С. Г., Козиолова Н. А., Маленкова В. Ю., Мальчикова С. В., Мареев Ю. В., Смирнова Е. А., Тарловская Е. И., Щербинина Е. В., Якушин С. С. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН// Кардиология. 2021. Т. 61, № 46. C. 4–14. https://doi.org/10.18087/cardio.2021.4.n1628
Драпкина О. М., Бойцов С. А., Омельяновский В. В., Концевая А. В., Лукьянов М. М., Игнатьева В. И., Деркач Е. В. Социально-экономический ущерб, обусловленный хронической сердечной недостаточностью, в Российской Федерации // Российский кардиологический журнал.2021. T. 26, № 6. C. 81–89. https://doi.org/10.15829/1560-4071-2021-4490
Кольцов А. В., Тыренко В. В., Сарана А. М., Язенок А. В., Коган Е. В., Ченцов Д. В. Распространенность сердечной недостаточности в условиях мегаполиса // Кардиология. 2022. Т. 62, № 125. C. 50–56. https://doi.org/10.18087/cardio.2022.12.n2294
Терещенко С. Н., Жиров И. В., Петрухина А. А. Клинико-демографические характеристики российской популяции амбулаторных пациентов с хронической сердечной недостаточностью на момент включения в регистр QUALIFY для оценки соблюдения клинических рекомендаций в отношении лекарственной терапии // Кардиология 2017. Т. 57, № 25. C. 324–330. https://doi.org/10.18087/cardio.2363
Greene S. J., Butler J., Albert N. M., DeVore A. D., Sharma P. P., Duffy C. I., Hill C. L., McCague K., Mi X.,Patterson J. H., Spertus J. A., Thomas L., Williams F. B., Hernandez A. F., Fonarow G. C. Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry // J. Am. Coll. Cardiol.2018. Vol. 72. P. 351–366.
Казаков А. С., Зырянов С. К., Ушкалова Е. А. Клинические рекомендации в свете нового законодательства // РМЖ. 2020. № 6. C. 15–19. URL: https://www.rmj.ru/articles/organizatsiyazdravookhraneniya-i obshchestvennoezdorove/Klinicheskie_rekomendacii_v_svete_novogo_zakonodatelystva/ (дата обращения: 20.02.2023).
Курочкина О. Н., Хохлов А. Л., Копылова Д. А., Богомолов А. Н. Медикаментозная терапия больных, перенесших инфаркт миокарда: врачебные назначения и приверженность пациентов // Вестник ВолгГМУ. 2012. Т. 4, № 44. С. 90–93. URL: https://cyberleninka.ru/article/n/medikamentoznaya-terapiya-bolnyh-perenesshih-infarkt-miokarda-vrachebnye-naznacheniya-ipriverzhennost-patsientov (дата обращения: 20.02.2023).
Greene S. J., Fonarow G. C., DeVore A. D., Sharma P. P., Vaduganathan M., Albert N. M., Duffy C. I.,Hill C. L., McCague K., Patterson J. H., Spertus J. A., Thomas L., Williams F. B., Hernandez A. F., Butler J.Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction // J. Am. Coll. Cardiol.2019. Vol. 73, no. 19. P. 2365–2383. https://doi.org/10.1016/j.jacc.2019.02.015
McDonagh T. A., Metra M., Adamo M., Gardner R. S., Baumbach A., Böhm M., Burri H., Butler J.,Čelutkienė J., Chioncel O., Cleland J. G. F., Coats A. J. S., Crespo-Leiro M. G., Farmakis D., Gilard M.,Heymans S., Hoes A. W., Jaarsma T., Jankowska E. A., Lainscak M., Lam C. S. P., Lyon A. R.,Ruschitzka F., Skibelund A. K. ESC Guidelines for the diagnosis and treatment of acute and chronicheart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heartfailure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC // European Heart Journal. 2021. Vol. 42, no. 36. P. 3599–3726. https://doi.org/10.1093/eurheartj/ehab368
McMurray J. J. V., Solomon S. D., Inzucchi S. E., Køber L., Kosiborod M. N., Martinez F. A., Ponikowski P.,Sabatine M. S., Anand I. S., Bělohlávek J., Böhm M., Chiang C.-E., Chopra V. K., de Boer R. A., Desai A. S.,Diez M., Drozdz J., Dukát A., Ge J., Howlett J. G., Katova T., Kitakaze M., Ljungman C. E. A., Merkely B.,Nicolau J. C., O’Meara E., Petrie M. C., Vinh P. N., Schou M., Tereshchenko S., Verma S., Held C.,DeMets D. L., Docherty K. F., Jhund P. S., Bengtsson O., Sjöstrand M., Langkilde A.-M. Dapagliflozin in patients with heart failure and reduced ejection fraction // N. Engl. J. Med. 2019. Vol. 381, no. 21.P. 1995–2008. https://doi.org/10.1056/NEJMoa1911303
Packer M., Anker S. D., Butler J., Filippatos G., Pocock S. J., Carson P., Januzzi J., Verma S., Tsutsui H.,Brueckmann M., Jamal W., Kimura K., Schnee J., Zeller C., Cotton D., Bocchi E., Böhm M., Choi D.-J.,Chopra V., Chuquiure E., Giannetti N., Janssens S., Zhang J., Gonzalez Juanatey J. R., Kaul S., Brunner-La Rocca H.-P., Merkely B., Nicholls S. J., Perrone S., Pina I., Ponikowski P., Sattar N., Senni M.,Seronde M.-F., Spinar J., Squire I., Taddei S., Wanner C., Zannad F. Cardiovascular and renal outcomes with empagliflozin in heart failure // N. Engl. J. Med. 2020. Vol. 383 (15). P. 1413–1414. https://doi.org/:10.1056/NEJMoa2022190
Anker S. D., Butler J., Filippatos G., Ferreira J. P., Bocchi E., Böhm M., Brunner-La Rocca H.-P., Choi D.-J.,Chopra V., Chuquiure-Valenzuela E., Giannetti N., Gomez-Mesa J. E., Janssens S., Januzzi J. L., Gonzalez-
Juanatey J. R., Merkely B., Nicholls S. J., Perrone S. V., Piña I. L., Ponikowski P., Senni M., Sim D., Spinar J.,Squire I., Taddei S., Tsutsui H., Verma S., Vinereanu D., Zhang J., Carson P., Lam C. S. P., Marx N.,Zeller C., Sattar N., Jamal W., Schnaidt S., Schnee J. M., Brueckmann M., Pocock S. J., Zannad F.,Packer M. Empagliflozin in Heart Failure with a Preserved Ejection Fraction // N. Engl. J. Med. 2021.Vol. 385. P. 1451–1461. https://doi.org/10.1056/NEJMoa2107038
Solomon S. D., McMurray J. J., Clagget B., de Boer R. A., DeMets D., Hernandez A. F., Inzucchi S. E.,Kosiborod M. N., Lam C. S. P., Martinez F., Shah S. J., Desai A. S., Jhund P. S., Belohlavek J., Chiang C.-E.,Borleffs C. J. W., Comin-Colet J., Dobreanu D., Drozdz J., Fang J. C., Alcocer-Gamba M. A., Al Habeeb W.,Han Y., Cabrera Honorio J. W., Janssens S. P., Katova T., Kitakaze M., Merkely B., O’Meara E., Saraiva J. F. K., Tereshchenko S. N., Thierer J., Vaduganathan M., Vardeny O., Verma S., Pham V. N., Wilderäng U., Zaozerska N., Bachus E., Lindholm D., Petersson M., Langkilde A. M. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction // N. Engl. J. Med. 2022. Vol. 387. P. 1089–1098. https://doi.org/10.1056/NEJMoa2206286
Kapelios C. J., Lund L. H., Benson L., Dahlström U., Rosano G. M. C., Hauptman P. J., Savarese G. Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry // European Heart Journal — Cardiovascular Pharmacotherapy. 2022. Vol. 8, no. 8.P. 756–767. https://doi.org/10.1093/ehjcvp/pvab079
Drechsler K., Dietz R., Klein H., Wollert K. C., Storp D., Molling J., Zeymer U., Niebauer J. Euro heart failure survey: Medical treatment not in line with current guidelines // Zeitschrift für Kardiologie.2005. Vol. 94, no. 8. P. 510–515. https://doi.org/10.1007/s00392‑005‑0245‑y
References
2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, vol. 25,no. 11, pp. 311–374. https://doi.org/10.15829/1560-4071-2020-4083 (In Russian)
Vinogradova N. G., Polyakov D. S., Fomin I. V. Analysis of mortality in patients with heart failure after decompensation during longterm follow-up in specialized medical care and in real clinical practice.Kardiologiia, 2020, vol. 60, no. 4, pp. 91–100. https://doi.org/10.18087/cardio.2020.4.n1014 (In Russian)
Groenewegen A., Rutten F. H., Mosterd A., Hoes A. W. Epidemiology of heart failure. European Journal of Heart Failure, 2020, vol. 22, no. 8, pp. 1342–1356. https://doi.org/10.1002/ejhf.1858
Polyakov D. S., Fomin I. V., Belenkov Yu. N., Mareev V. Yu., Ageev F. T., Artemjeva E. G., Badin Yu. V.,Bakulina E. V., Vinogradova N. G., Galyavich A. S., Ionova T. S., Kamalov G. M., Kechedzhieva S. G.,Koziolova N. A., Malenkova V. Yu., Malchikova S. V., Mareev Yu. V., Smirnova E. A., Tarlovskaya E. I.,Shcherbinina E. V., Yakushin S. S. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia, 2021, vol. 61, no. 4,pp. 4–14. https://doi.org/10.18087/cardio.2021.4.n1628 (In Russian)
Drapkina O. M., Boytsov S. A., Omelyanovskiy V. V., Kontsevaya A. V., Loukianov M. M., Ignatieva V. I.,Derkach E. V. Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology, 2021,vol. 26, no. 6, pp. 81–89. https://doi.org/10.15829/1560-4071-2021-4490 (In Russian)
Koltsov A. V., Tyrenko V. V., Sarana A. M., Yazenok A. V., Kogan E. I., Chentsov D. V. Prevalence of Heart Failure in a Megalopolis. Kardiologiia, 2022, vol. 62, no. 12, pp. 50–56. https://doi.org/10.18087/ cardio.2022.12.n2294 (In Russian)
Tereshchenko S. N., Zhirov I. V., Petrukhina A. A. Clinical and demographic characteristics of an outpatient Russian population with chronic heart failure at the time of enrollment in the QUALIFY registry for evaluating consistency with clinical guidelines on drug therapy. Kardiologiia, 2017, vol. 57,no. 25, pp. 324–330. https://doi.org/10.18087/cardio.2363 (In Russian)
Greene S. J., Butler J., Albert N. M., DeVore A. D., Sharma P. P., Duffy C. I., Hill C. L., McCague K.,Mi X., Patterson J. H., Spertus J. A., Thomas L., Williams F. B., Hernandez A. F., Fonarow G. C. Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry. J. Am. Coll. Cardiol., 2018, vol. 72, pp. 351–366.
Kazakov A. S., Zyiryanov S. K., Ushkalova E. A. Clinical practice guidelines in the light of novel legislation.Russian Medical Journal, 2020, vol. 6, pp. 15–19. Available at: https://www.rmj.ru/articles/organizatsiya-zdravookhraneniya-i-obshchestvennoe zdorove/Klinicheskie_rekomendacii_v_svete_novogo_zakonodatelystva/ (accessed: 20.02.2023). (In Russian)
Kurochkina O. N., Khokhlov A. L., Kopylova D. A., Bogomolov A. N. Drug therapy of patients after myocardial infarction: medical prescriptions and patient adherence. Vestnik VolgGMU. 2012, vol.4, no. 44, pp. 90–93. Available at: https://cyberleninka.ru/article/n/medikamentoznaya-terapiyabolnyh-perenesshih-infarkt-miokarda-vrachebnye-naznacheniya-i-priverzhennost-patsientov (accessed:20.02.2023). (In Russian)
Greene S. J., Fonarow G. C., DeVore A. D., Sharma P. P., Vaduganathan M., Albert N. M., Duffy C. I.,Hill C. L., McCague K., Patterson J. H., Spertus J. A., Thomas L., Williams F. B., Hernandez A. F., Butler J. Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction. J. Am. Coll. Cardiol., 2019, vol. 73, no. 19, pp. 2365–2383. https://doi.org/10.1016/j.jacc.2019.02.015
McDonagh T. A., Metra M., Adamo M., Gardner R. S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., Cleland J. G. F., Coats A. J. S., Crespo-Leiro M. G., Farmakis D., Gilard M.,Heymans S., Hoes A. W., Jaarsma T., Jankowska E. A., Lainscak M., Lam C. S. P., Lyon A. R., McMurray J. J. V., Mebazaa A., Mindham R., Muneretto C., Piepoli M. F., Price S., Rosano G. M. C., Ruschitzka F., Skibelund A. K. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2021, vol. 42, no. 36, pp. 3599–3726. https://doi.org/10.1093/eurheartj/ehab368
McMurray J. J. V., Solomon S. D., Inzucchi S. E., Køber L., Kosiborod M. N., Martinez F. A., Ponikowski P.,Sabatine M. S., Anand I. S., Bělohlávek J., Böhm M., Chiang C.-E., Chopra V. K., de Boer R. A., Desai A. S., Diez M., Drozdz J., Dukát A., Ge J., Howlett J. G., Katova T., Kitakaze M., Ljungman C. E. A., Merkely B., Nicolau J. C., O’Meara E., Petrie M. C., Vinh P. N., Schou M., Tereshchenko S., Verma S., Held C., DeMets D. L., Docherty K. F., Jhund P. S., Bengtsson O., Sjöstrand M., Langkilde A.-M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 2019, vol. 381,no. 21, pp. 1995–2008. https://doi.org/10.1056/NEJMoa1911303
Packer M., Anker S. D., Butler J., Pocock S. J., Carson P., Januzzi J., Verma S., Tsutsui H., Brueckmann M.,Jamal W., Kimura K., Schnee J., Zeller C., Cotton D., Bocchi E., Böhm M., Choi D.-J., Chopra V.,Chuquiure E., Giannetti N., Janssens S., Zhang J., Gonzalez Juanatey J. R., Kaul S., Brunner-La Rocca H.-P., Merkely B., Nicholls S. J., Perrone S., Pina I., Ponikowski P., Sattar N., Senni M., Seronde M.-F., Spinar J., Squire I., Taddei S., Wanner C., Zannad F. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med., 2020, vol. 383, no. 15, pp. 1413–1424. https://doi.org/10.1056/NEJMoa2022190
Anker S. D., Butler J., Filippatos G., Ferreira J. P., Bocchi E., Böhm M., Brunner-La Rocca H.-P., Choi D.-J.,Chopra V., Chuquiure-Valenzuela E., Giannetti N., Gomez-Mesa J. E., Janssens S., Januzzi J. L., Gonzalez-Juanatey J. R., Merkely B., Nicholls S. J., Perrone S. V., Piña I. L., Ponikowski P., Senni M., Sim D.,Spinar J., Squire I., Taddei S., Tsutsui H., Verma S., Vinereanu D., Zhang J., Carson P., Lam C. S. P.,Marx N., Zeller C., Sattar N., Jamal W., Schnaidt S., Schnee J. M., Brueckmann M., Pocock S. J., ZannadF., Packer M. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med.,2021, vol. 385, pp. 1451–1461. https://doi.org/10.1056/NEJMoa2107038
Solomon S. D., McMurray J. J. V., Claggett B., de Boer R. A., DeMets D., Hernandez A. F., Inzucchi S. E.,Kosiborod M. N., Lam C. S. P., Martinez F., Shah S. J., Desai A. S., Jhund P. S., Belohlavek J., Chiang C.-E., Borleffs C. J. W., Comin-Colet J., Dobreanu D., Drozdz J., Fang J. C., Alcocer-Gamba M. A., Al Habeeb W., Han Y., Cabrera Honorio J. W., Janssens S. P., Katova T., Kitakaze M., Merkely B.,O’Meara E., Saraiva J. F. K., Tereshchenko S. N., Thierer J., Vaduganathan M., Vardeny O., Verma S.,Pham V. N., Wilderäng U., Zaozerska N., Bachus E., Lindholm D., Petersson M., Langkilde A. M. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J. Med.,vol. 387, pp. 1089–1098. https://doi.org/10.1056/NEJMoa2206286
Kapelios C. J., Lund L. H., Benson L., Dahlström U., Rosano G. M. C., Hauptman P. J., Savarese G. Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry. European Heart Journal — Cardiovascular Pharmacotherapy, 2022, vol. 8, no. 8,pp. 756–767, https://doi.org/10.1093/ehjcvp/pvab079
Drechsler K., Dietz R., Klein H., Wollert K. C., Storp D., Molling J., Zeymer U., Niebauer J. Euro heart failure survey: Medical treatment not in line with current guidelines. Zeitschrift für Kardiologie, 2005,vol. 94, no. 8, pp. 510–515. https://doi.org/:10.1007/s00392‑005‑0245‑y
Downloads
Published
2023-06-15
How to Cite
Tregubov, A., Krasnova, O., & Chernyakova, A. (2023). The practice of the clinical guidelines for the diagnosis and treatment of chronic heart failure applying in the city hospitals of Saint Petersburg. Vestnik of Saint Petersburg University. Medicine, 18(1), 12–27. https://doi.org/10.21638/spbu11.2023.102
Issue
Section
Internal medicine
License
Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.
